ClinicalTrials.gg
RecruitingNCT07453784Updated Nov 13, 2026

Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet Formulation

A Phase 1 interventional study of Obefazimod 50 mg Capsule and Obefazimod Minitablet 50 mg in Healthy, sponsored by Abivax S.A.. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Abivax S.A. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Nov 13, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The sponsor is developing a pediatric minitablet formulation as part of the overall pharmaceutical development strategy. In vitro dissolution and physiological-based bio-pharmaceutics modelling and simulation have been used to guide the development of the mini-tablet formulation to match the PK exposure of the adult capsule formulation. The study aims to investigate the relative bioavailability of the 50mg minitablet compared to the adult obefazimod 50 mg capsule in adult healthy volunteers.

Read the detailed description

This is a single center, open-label, two-part study in healthy male and female participants.

Part 1 of this study aims to investigate the PK properties of single dose of obefazimod 50 mg minitablet formulation and to identify a dose that provides systemic exposures (Cmax and AUC) comparable to that of the adult clinical obefazimod 50 mg capsule formulation.

In part 2, the minitablet formulation will be administered with a soft food vehicle (applesauce, yogurt or chocolate pudding or water) to investigate the relative bioavailability of the 50mg minitablet mixed with water or soft foods compared to the adult obefazimod 50 mg capsule administered with no vehicle.

02

Conditions studied

  • Healthy

Keywords

  • Healthy participants
  • obefazimod
  • minitablet
03

In context

Lead sponsor

Abivax S.A. is the lead sponsor of 23 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 55 years inclusive at the time of signing
  • Must agree to adhere to the requirements.
  • Healthy male or non-pregnant, non-lactating female participants according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs, 12-lead and laboratory safety tests without any abnormalities
  • (BMI) of 18.0 to 32.0 kg/m2 as measured at screening
  • Weight ≥50 kg at screening Inclusion criteria.

Exclusion criteria

Exclusion Criteria:

  • Presence or history of allergy requiring treatment, as judged by the investigator.
  • History of clinically significant cardiovascular, renal, hepatic, dermatological, respiratory or GI disease, neurological or psychiatric disorder, as judged by the investigator
  • Participants with a history of cholecystectomy or gall stones
  • Participants with chronic or recurrent infection
  • Participants who have tested positive for tuberculosis
  • Participants with a history of shingles within the last two months
  • History of opportunistic infection while not on therapy
  • Part 2 only: Participant has a medical condition that may adversely affect taste or smell activity including but not limited to mouth ulcers, significant gum disease, and respiratory and/or sinus infection or cold
  • Part 2 only: Participant does not agree to the consumption of, or has any known allergies to any of the food vehicles used in this study (applesauce, chocolate pudding, yogurt)
  • Participants who have received any IMP ( Medicinal Product) in a clinical research study within the 90 days prior to Day 1, or less than 5 elimination half-lives prior to Day 1, whichever is longer
  • Participants who have previously been administered IMP in this study
  • Donation of blood or plasma within the previous 3 months or loss of greater than 400 mL of blood
  • Participants who are taking, or have taken, any prescribed or over-the-counter drug, hormone replacement therapy (HRT) or herbal remedies (other than up to 4 g of paracetamol per day and hormonal ) in the 14 days or 5 elimination half-lives, whichever is longer, before first IMP administration (see Section 11.4). Exceptions may apply, as determined by the investigator
  • Having any vaccination or planned vaccination within 28 days before Day 1. Participants who received within 3 months prior to screening and/or who are planning to receive such a vaccine during the study duration.
  • History of any drug or alcohol abuse in the past 2 years
  • Regular alcohol consumption in males >21 units per week and in females >14 units per week (1 unit = ½ pint beer, or a 25 mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type)
  • Current smokers and those who have smoked within the last 12 months
  • Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months
  • Confirmed positive drugs of abuse test result at screening or admission
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    Obefazimod 50 mg Capsule Adult Formulation

    Participants will receive a single oral dose of obefazimod Capsule administered with water

    Drug: Obefazimod 50 mg Capsule

  • Experimental
    Obefazimod Minitablet 50 mg

    Participants will receive a single oral dose of obefazimod Minitablet with either Apple sauce, Chocolate pudding, Yogurt, Water

    Drug: Obefazimod Minitablet 50 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax)

    Cmax of obefazimod in the Minitablet and Capsule regimens

    Time frame: Up to 336 hours post-dose (Day 15) at each period

  2. Area under the plasma concentration versus time curve from time zero up to the last measurable concentration (AUC (0-last)

    AUC (0-last) of obefazimod in the Minitablet and Capsule regimens

    Time frame: Up to 336 hours post-dose (Day 15) at each period

  3. Area under the plasma concentration versus time curve up from time zero to infinity [AUC(0-inf)]

    AUC(0-inf) of obefazimod in the Minitablet and Capsule regimens

    Time frame: Up to 336 hours post-dose (Day 15) at each period

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Mar 2026 (actual). Primary completion is estimated for Apr 2027, 13 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Sep 2026 → Apr 2027 and completion Oct 2026 → Apr 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2026
First posted
Mar 6, 2026
StartActual
Mar 3, 2026
Primary completionEst.
Apr 2027was Sep 2026
CompletionEst.
Apr 2027was Oct 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Apr 2027
Nov 13, 2026
Study completion
Oct 2026→Apr 2027
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Primary completion Sep 2026→Apr 2027
    Study completion Oct 2026→Apr 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07453784
Lead sponsor
Abivax S.A.
Collaborators
Quotient Sciences
Responsible party
Sponsor
First posted
Mar 6, 2026
Start date
Mar 3, 2026
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Josianne Nitcheu
Contact
josianne.nitcheu@abivax.com
33781759766

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABX464

Start the discussion